ESPITE the contemporary management of ruptured cerebral aneurysms, cerebral vasospasm is still the leading cause of high morbidity and mortality rates following SAH. An association between the release of blood breakdown products in the subarachnoid space and vasospasm has been established; however, the precise pathopysiological mechanisms for this and what elements have roles in the development of vasospasm remain to be elucidated. The cumulative body of evidence in recent years has indicated that by regulating inflammation, adhesion molecules play a crucial role in the development of vasospasm after SAH due to an aneurysm rupture. 2, 9, 10, 15, 16, 19, 22 The upregulation of adhesion molecules has been shown in various inflammatory cerebral diseases, including bacterial meningitis, encephalitis, and multiple sclerosis. 2, 9, 22 The expression of adhesion molecules on the endothelium and vessel wall in atherosclerotic lesions and in ischemia-reperfusion injury has also been demonstrated, supporting the notion that these molecules play an important role in the immune-mediated inflammatory cascade of events. 3, 6, 8 During the last decade, experimental studies have implicated adhesion molecules in the development of vasospasm after SAH. Handa and associates 10 demonstrated significant expression of ICAM-1 on the endothelial layer of the BA following SAH induced by an intracisternal injection of arterial blood in rats. Sills, et al.,
1, a surface molecule of leukocytes that interacts with ICAM-1, in an FA model in rats. In a recent study, the prevention of cerebral vasospasm by a humanized anti-CD11/ CD18 mAb administered after experimental SAH in nonhuman primates was shown. 4 Although encouraging findings from these experimental studies have been obtained, the putative role of adhesion molecules in human vasospasm following aneurysmal SAH is not yet adequately known. Polin, et al., 18 demonstrated elevation of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the CSF of patients after aneurysmal SAH. Nissen and colleagues 16 demonstrated that P-and L-selectin are increased in the serum of patients after aneurysmal SAH and proposed that these selectin superfamilies, rather than ICAM-1 and VCAM-1, may be involved in the pathophysiology of DIND after SAH. Mack, et al., 14 found a correlation between soluble ICAM-1 levels in serum and functional outcomes in patients following aneurysmal SAH. Mocco and coworkers 15 have also shown the same correlation in patients with vasospasm, evidenced by daily monitoring of TCD velocities. In addition, a strong correlation between clinical outcome and the concentrations of soluble adhesion molecules in the CSF of patients with acute intracerebral hemorrhage has also been demonstrated. The results of these experimental and clinical studies strongly indicate that adhesion molecules may be involved in the pathogenesis of vasospasm after aneurysmal rupture.
In this prospective clinical study, our aim was to examine soluble ICAM-1 and VCAM-1 levels in the CSF and serum of patients at various time points after aneurysmal SAH.
Material and Methods

Patient Population
Ethical approval for this study was obtained from the Human Investigations Committee at Istanbul University, and all patients or the next of kin, if the patient was unconscious, provided informed consent. We studied patients who were referred to our neurosurgical unit between January and June 2003 with the diagnosis of SAH established by computerized tomography scanning. We excluded patients who had any kind of infection at the time of CSF and serum collection, in which adhesion molecules might play a part. The sole inclusion criterion was admission of the patients to our unit within the first 3 days of SAH.
Demographics of Patients and the Control Group
The study population consisted of 21 patients with aneurysmal SAH and 15 patients with hydrocephalus without any other known CNS diseases. Among the patients with SAH, seven had ACoA aneurysms, four had PCoA aneurysms, four had MCA bifurcation aneurysms, three had ICA aneurysms, one had an ophthalmic artery aneurysm, one had both ICA and MCA aneurysms, and one had both ACoA and MCA aneurysms.
The average age of the patients with SAH was 46.4 years (range 17-71 years). The Glasgow Outcome Scale, 13 which was applied to these patients at hospital discharge, showed good recovery in 11 patients, mild disability in three, and severe disability in two. Four patients died before discharge and one demonstrated a persistent vegetative state.
The average age of the control group was 50.2 years (range 15-81 years). Nine patients had normotensive hydrocephalus and six had hydrocephalus due to aqueduct stenosis. Summaries of demographic information for the patients with SAH and the control group are provided in Tables 1 and 2 , respectively.
Specimen Handling
Seventy-eight (total 156) samples were assayed for ICAM-1 and 78 for VCAM-1. For each patient, serial blood and CSF samples were collected at the same time within 3 days and on the 5th and 7th days post-SAH. The blood and CSF samples were collected by venipuncture and lumbar puncture, respectively. In the control group, the blood samples were collected by venipuncture and the CSF samples were obtained during ventriculoperitoneal shunt placement surgery. Samples from the control group were obtained only once. As soon as possible, each 10-ml CSF and blood specimen was centrifuged at 10,000 rpm for 15 minutes and the supernatant was stored at Ϫ70˚C until assayed. 1  65, F  III  2  yes  PCoA  death  2  67, F  II  3  no  ACoA  good recovery  3  58, M  III  3  yes  ICA  severe disability  4  71, F  V  3  yes  MCA  death  5 67 
Statistical Analysis
Data were analyzed with the aid of the SPSS statistical program (SPSS, Chicago, IL). Statistical analyses were performed using the nonparametric Mann-Whitney U-test. A probability value less than 0.05 was considered statistically significant.
Results
Sixty-three CSF and 63 serum samples from patients with SAH and 15 CSF and 15 serum samples from patients in the control group were obtained for this prospective clinical study. The samples were tested for the presence of ICAM-1 and VCAM-1. The results in the SAH and control groups are provided in Tables 3 and 4 , respectively, and a summary of the statistical data is provided in Table 5 . Graphic representations of the ICAM-1 and VCAM-1 levels in CSF and serum in patients in the SAH and control groups are provided in Figs. 1 and 2.
Levels of ICAM-1 in CSF
The CSF levels of ICAM-1 markedly differed between in the SAH and control groups. In the control group, CSF samples from three patients had no detectable quantity of ICAM-1 and the mean concentration of this adhesion molecule was 2.48 Ϯ 3.15 ng/ml. In contrast, CSF samples from all patients who had experienced SAH had quantifiable ICAM-1 during the first 3 days and on the 5th and 7th days post-SAH. The mean values in this group were 28.06 Ϯ 5.8 ng/ml within the first 3 days, 35.17 Ϯ 7.1 ng/ ml on Day 5, and 47.46 Ϯ 8.8 ng/ml on Day 7. This difference in concentrations between groups was statistically significant (p = 0.00001). In addition the mean elevated levels of ICAM-1 measured post-SAH at the three time points were statistically significant when compared with each other (p = 0.00001).
Levels of ICAM-1 in Serum
The levels of ICAM-1 in the serum of patients in the SAH and control groups were also markedly different. The mean concentration of ICAM-1 in the control patients was 182.46 Ϯ 21.65 ng/ml compared with 414.43 Ϯ 7.46, 442.76 Ϯ 9.73, and 481.57 Ϯ 13.82 ng/ml in the SAH group within the first 3 days and on the 5th and 7th days after the hemorrhage, respectively. The differences in concentration between the two groups of patients was statistically significant (p = 0.00001). In addition, the mean elevated levels of serum soluble ICAM-1 measured post-SAH at the three time points were statistically significant when compared with each other (p = 0.00001).
Levels of VCAM-1 in CSF
The levels of VCAM-1 averaged 24.5 Ϯ 17.9 ng/ml in the control group compared with 48.55 Ϯ 6.48, 53.89 Ϯ 6.58, and 60.30 Ϯ 6.52 ng/ml in the SAH group within the first 3 days and on the 5th and 7th days posthemorrhage, respectively. This difference in levels between the patient groups was statistically significant (p = 0.009). In addition the differences among the mean elevated levels of VCAM-1 measured at the three time points post-SAH were also statistically significant (p = 0.00001).
Levels of VCAM-1 in Serum
The levels of VCAM-1 in the serum of patients with SAH were significantly elevated when compared with levels in the control group. In the control group, the mean levels of VCAM-1 were 361.66 Ϯ 41.38 ng/ml. In contrast, in patients with SAH these levels were 598.9 Ϯ 14.51, 615.0 Ϯ 14.82, and 625.86 Ϯ 20.12 ng/ml within the first 3 days and on the 5th and 7th days post-SAH, respectively. Comparisons between the levels measured on those 3 days and the level in the control group provided statistically significant differences (p = 0.00001). When we compared the elevated level of VCAM-1 measured within the first 3 days with levels measured on Day 5 and Day 7, there was a statistically significant difference (p = 0.00001 and p = 0.01, respectively). When we compared the elevated level measured on Day 5 with that measured on Day 7 post-SAH, however, no statistically significant difference was demonstrated (p = 0.27).
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FIG. 1. Graph showing a comparison of levels of ICAM-1 and VCAM-1 in the CSF of patients with SAH and control patients.
Squares represents the means Ϯ standard errors of the means and bars denote the range of values. The differences in the levels of these adhesion molecules between the two groups of patients were statistically significant (for ICAM-1 p Ͻ 0.00001; for VCAM-1 p Ͻ 0.009).
Other Factors
In this study, the SAH group was composed of eight male and 13 female patients with a mean age of 46.4 years, and the control group included seven male and eight female patients with a mean age of 50.2 years. There was no statistically significant difference between groups with regard to age or sex (p = 0.5 for age and p = 0.6 for sex). Among these patients, age and sex; Fisher grade; 7 Hunt and Hess grade 12 at presentation; history of hypertension, coronary artery disease, diabetes mellitus, or smoking; leukocytosis on admission; symptomatic vasospasm; and the GOS score had no effect on elevated levels of ICAM-1 and VCAM-1. Table  6 summarizes data for a comparison of levels of adhesion molecules in the control group and in patients in the SAH group with poor outcomes. Discussion Two members of the immunoglobulin superfamily, ICAM-1 and VCAM-1, are known to be adhesion molecules thought to participate in the pathogenesis of vasospasm after SAH. Detailed descriptions on the location and function of each of these molecules have appeared in the literature. It is beyond the scope of this paper to provide similar detailed descriptions, but suffice to state that ICAM-1 can be induced by interleukin-1, interferon-␥, and tumor necrosis-␣, and is mainly expressed by the vascular endothelium, macrophages, and lymphocytes. By binding to its ligand, CD18, which is present on circulating leukocytes, ICAM-1 causes firm adhesion of leukocytes to the vascular endothelium and mediates diapedesis, which is known to be one of the most crucial steps in the inflammatory process. On the other hand, VCAM-1 is expressed on the vascular endothelium in response to cytokine production, and binds to its ligand, late antigen-4, which is expressed on lymphocytes and monocytes. The main function of this adhesion molecule is to support adhesion. 11, 21 The involvement of the immune-inflammatory response has been implicated in the pathogenesis of vasospasm after SAH in both animal and human studies. Handa and associates 10 showed the induction of ICAM-1 expression on the endothelium, media, and adventitia of the BA after SAH, which was induced by an intracisternal injection of blood in rats. In their study, a correlation between the degree and timing of arterial spasm and the leukocyte inflammatory response was also demonstrated. In an FA model of vasospasm in rats, Sills, et al., 19 demonstrated early induction of ICAM-1 on the vessel endothelium. At that study the influx of inflammatory cells was correlated with the time and location of increased ICAM-1 expression. Furthermore, in recent years, the upregulation of adhesion molecules has also been shown in ischemia-reperfusion injury models and a variety of cerebral inflammatory diseases in humans. 2, 8, 9, 22 In animal studies these findings indicate that expression of adhesion molecules may play a pivotal role in inflammation in the CNS and may cause or initiate vasospasm after SAH. The results of these animal studies have led to the development of antiadhesion strategies, which seemed to provide satisfactory results. Oshiro and colleagues 17 demonstrated that anti-ICAM-1 mAbs, which were administered systemically starting 3 hours after exposure of blood to the FA, resulted in a significant inhibition of vasospasm in the rat FA model. This inhibition was also correlated with a reduction in the number of infiltrating macrophages and granulocytes in the periadventitial space of the blood-exposed vessel. In a rabbit model of SAH, Bavbek, et al., 1 reported attenuation of vasospasm following an intracisternal administration of mAbs directed against ICAM-1 and its ligand, CD18. Using the same model, Clatterbuck, et al., 5 demonstrated the ability to block vasospasm of the FA by using mAbs to LFA-1, the molecule on the surface of leukocytes that interacts with ICAM-1. In a more recent study, Clatterbuck, et al., 4 extended their previous work involving the systemic administration of an mAb for a blockade of leukocyte migration to a nonhuman primate model of chronic, posthemorrhagic cerebral vasospasm. Those researchers demonstrated that administration of humanized anti-LFA-1 and macrophage antigen-1, which are expressed on the surface of a leukocyte, prevents experimental cerebral vasospasm in nonhuman primates, despite the unaltered presence of hemoglobin in the subarachnoid space. The downregulation of ICAM-1 by a periadventitial release of ibuprofen, a nonselective cyclooxygenase inhibitor, has also been proven. 20 These experimental studies, in which antiadhesion molecule strategies were used, clearly support the hypothesis that inflammation plays a role in cerebral vasospasm after SAH.
Despite the growing body of evidence from animal studies that demonstrate the importance of leukocyte-endothelial adhesion molecule interaction in the molecular chain of events leading to posthemorrhagic vasospasm, a limited number of human studies have provided evaluations of ICAM-1 and VCAM-1, both of which have been shown to have a crucial role in the development of vasospasm after aneurysmal SAH. It may be possible that animal models of SAH produce vasospasm that differs from that observed in humans in both time course and anatomy. Therefore, it is clear that clinical studies designed to evaluate adhesion molecules in patients with aneurysmal SAH may provide direct evidence. For this purpose, some investigators have begun to perform clinical studies to explore whether lev-els of soluble adhesion molecules, particularly ICAM-1 and VCAM-1, are elevated in CSF or blood after SAH and to evaluate the role of regulating leukocyte adhesion to, and migration across, the vascular endothelium. The first clinical prospective study was performed by Polin, et al., 18 who showed elevated levels of soluble ICAM-1, VCAM-1, E-selectin, and L-selectin in the CSF of 17 patients after SAH when compared with 16 control patients. The increase in adhesion molecules was more pronounced for ICAM-1 and E-selectin than for VCAM-1 and L-selectin. The authors concluded that the expression of adhesion molecules, particularly ICAM-1 and E-selectin, may be a critical step in the inflammatory process that occurs after SAH in humans. In a recent prospective study, mean serum concentrations of ICAM-1; VCAM-1; platelet-endothelial adhesion molecule; and E-, P-, and L-selectin were compared between patients with and without DIND after aneurysmal SAH. Of all the adhesion molecules tested in this study, P-and L-selectin were thought to be involved in the pathophysiology of DIND. Although the results for ICAM-1 and VCAM-1 were not statistically significant, they did demonstrate a strong statistical trend in patients with DIND. 16 Mack, et al., 14 showed a significant correlation between serum ICAM-1 levels and outcomes in patients with SAH. According to these authors, serum soluble ICAM-1 levels appear to be strong predictors of poor outcome in patients with Hunt and Hess Grades I and II. In a more recent clinical study, Mocco and coworkers 15 examined soluble ICAM-1 levels at various time points after aneurysmal SAH, and analyzed them with respect to changes in vessel flow dynamics and morphological characteristics by monitoring TCD velocities and performing cerebral angiography. In patients in whom vasospasm was documented by both TCD studies and angiography a highly significant mean rate of increase in soluble ICAM-1 levels was found during the perivasospasm period.
Positive findings in these animal and human studies led us to investigate whether both CSF and serum concentrations of adhesion molecules are increased and can be correlated with Hunt and Hess neurological grade, degree of SAH (Fisher grade), symptomatic vasospasm, and outcome. Moreover, this is the first prospective clinical study in which an attempt has been made to investigate soluble ICAM-1 and VCAM-1 in both CSF and serum in patients after aneurysmal SAH. Cerebrospinal fluid and serum concentrations of ICAM-1 are significantly higher in patients with SAH compared with control patients. The concentrations continued to increase at all time points at which ICAM-1 was measured. The same is true for VCAM-1. The increased levels of ICAM-1 and VCAM-1 in both CSF and serum may indicate that the process leading to a post-SAH cascade occurs in local (brain) and systemic compartments. Because of the vascular endothelial damage and bloodbrain barrier breakdown that occur after SAH, these adhesion molecules can be shed into the CSF. Thus, the migration of inflammatory cells into the CNS, in addition to local destruction of the vascular endothelium and leukocytes in the subarachnoid space, may be the origin of increased CSF levels of ICAM-1 and VCAM-1. Similarly, shedding of these two molecules into the systemic circulation may partly explain the origin of increased serum levels of such molecules. Whether the increase in levels of ICAM-1 and VCAM-1 is simply a byproduct produced by vasospasm or represents a signal initiating inflammation and leading to vasospasm remains to be elucidated. Currently, the only evidence in hand to indicate the latter is the ability of antibodies to ICAM-1 and its ligand, CD18, to lessen experimental vasospasm in the rabbit, 1 FA, 4 and primate 5 models. The relevance of such experimental studies to human vasospasm has not yet been demonstrated. Additional experimental studies must be performed to find whether these molecules are involved in the pathogenesis of vasospasm or merely appear as byproducts before any clinical application of anti-ICAM-1 and anti-VCAM-1 treatment can be made. Although the adhesion molecules tested in our study did not differ statistically when Fisher grade, symptomatic vaso- spasm, and outcome at 6 months were reviewed, patients with particularly high CSF levels of ICAM-1 (SAH Cases 4, 5, 6, 14, and 18) and high CSF levels of VCAM-1 (SAH Cases 5, 6, and 18) had Fisher Grade 3, unfavorable outcome, and/or symptomatic vasospasm. Data on adhesion molecules obtained in only these five patients can hardly provide proof of such a relationship, but the results may provide a strong impetus for additional clinical investigations of such a possibility. A positive correlation seems to be present between the elevated levels of adhesion molecules, particularly ICAM-1, and poor outcome; however, the reason for this poor outcome has not yet been explained clearly. Investigators have hypothesized that this relationship may be ascribed to the role ICAM-1 plays in the pathophysiology of human vasospasm. [14] [15] [16] 18 We insist that the statistically insignificant relationship between outcome and the levels of adhesion molecules evaluated in our study may be due to the small number of patients with SAH. Another interesting finding seen in our study is that there was no correlation between the measured levels of adhesion molecules and initial leukocytosis. Such conflicts also may be attributed to the small number of the patients studied here.
Conclusions
Elevated levels of ICAM-1 and VCAM-1 in both CSF and serum may indicate that the process leading to poor outcome occurs in the brain and systemic circulation. Based on our results, we therefore suggest that application of anti-ICAM-1 and anti-VCAM-1 treatments delivered systemically or intrathecally may be helpful. Additional studies are required to elucidate whether adhesion molecules are the consequence of vasospasm or vice versa. As the pathophysiological sequence of events leading to vasospasm after SAH becomes better understood, it is possible that VCAM-1 and ICAM-1 will provide novel therapeutic targets for antivasospasm management in the future. In addition, it seems that it may be essential to obtain control values of these molecules from healthy volunteers associated with larger patient cohorts for a better understanding of the role of such molecules.
